Patrick M. Sexton

List of Publications by Year
in descending order

394	23,534	7568 77	11939 134
papers	citations	h-index	g-index

430	430	430	15470
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Functional Selectivity and Classical Concepts of Quantitative Pharmacology. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1-13.	2.5	997
2	Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature, 2013, 504, 101-106.	27.8	779
3	International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors. Pharmacological Reviews, 2002, 54, 233-246.	16.0	714
4	Allosteric Modulation of G Proteinâ€“Coupled Receptors. Annual Review of Pharmacology and Toxicology, 2007, 47, 1-51.	9.4	615
5	Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nature Reviews Molecular Cell Biology, 2018, 19, 638-653.	37.0	457
6	Multiple Amylin Receptors Arise from Receptor Activity-Modifying Protein Interaction with the Calcitonin Receptor Gene Product. Molecular Pharmacology, 1999, 56, 235-242.	2.3	456
7	Phase-plate cryo-EM structure of a class B GPCRâ€“G-protein complex. Nature, 2017, 546, 118-123.	27.8	424
8	Emerging paradigms in GPCR allostery: implications for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 630-644.	46.4	396
9	Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature, 2013, 503, 295-299.	27.8	365
10	G-Proteinâ€“Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. Circulation, 2005, 111, 1806-1813.	1.6	346
11	Muscarinic acetylcholine receptors: novel opportunities for drug development. Nature Reviews Drug Discovery, 2014, 13, 549-560.	46.4	337
12	Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends in Pharmacological Sciences, 2007, 28, 382-389.	8.7	330
13	Novel Receptor Partners and Function of Receptor Activity-modifying Proteins. Journal of Biological Chemistry, 2003, 278, 3293-3297.	3.4	283
14	Structure of the adenosine-bound human adenosine A1 receptorâ€“Gi complex. Nature, 2018, 558, 559-563.	27.8	274
15	Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature, 2016, 531, 335-340.	27.8	272
16	The role of kinetic context in apparent biased agonism at GPCRs. Nature Communications, 2016, 7, 10842.	12.8	270
17	Status of GPCR Modeling and Docking as Reflected by Community-wide GPCR Dock 2010 Assessment. Structure, 2011, 19, 1108-1126.	3.3	269
18	Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptorâ€“Gs complex. Nature, 2018, 555, 121-125.	27.8	263

#	Article	IF	Citations
19	Structural insights into G-protein-coupled receptor allostery. Nature, 2018, 559, 45-53.	27.8	255
20	Glucagon-Like Peptide-1 and Its Class B G Proteinâ€“Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews, 2016, 68, 954-1013.	16.0	252
21	In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience, 1994, 62, 553-567.	2.3	247
22	Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. Cell, 2017, 168, 867-877.e13.	28.9	237
23	Allosteric modulation of G protein-coupled receptors: A pharmacological perspective. Neuropharmacology, 2011, 60, 24-35.	4.1	235
24	GPCR modulation by RAMPs. , 2006, 109, 173-197.		213
25	Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature, 2018, 561, 492-497.	27.8	210
26	Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5211-5216.	7.1	203
27	Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes. Molecular Pharmacology, 2005, 67, 1655-1665.	2.3	196
28	Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening. Molecular Pharmacology, 2010, 78, 456-465.	2.3	195
29	International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. Pharmacological Reviews, 2014, 66, 918-947.	16.0	189
30	Novel Allosteric Modulators of G Protein-coupled Receptors. Journal of Biological Chemistry, 2015, 290, 19478-19488.	3.4	173
31	Receptor activity modifying proteins. Cellular Signalling, 2001, 13, 73-83.	3.6	166
32	A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity. Journal of Biological Chemistry, 2008, 283, 29312-29321.	3.4	165
33	Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends in Pharmacological Sciences, 2013, 34, 59-66.	8.7	150
34	RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. , 2008, 119, 7-23.		149
35	Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias. Journal of Biological Chemistry, 2010, 285, 7459-7474.	3.4	149
36	The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Proteinâ€“Coupled Receptors. Annual Review of Pharmacology and Toxicology, 2012, 52, 153-178.	9.4	148

#	Article	IF	Citations
37	Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties. Neuropsychopharmacology, 2010, 35, 855-869.	5.4	143
38	DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacology and Translational Science, 2018, 1, 61-72.	4.9	143
39	Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor. Endocrinology, 2012, 153, 1232-1241.	2.8	142
40	Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands. Journal of Biological Chemistry, 2007, 282, 25677-25686.	3.4	137
41	Receptor Activity-Modifying Proteins Differentially Modulate the G Protein-Coupling Efficiency of Amylin Receptors. Endocrinology, 2008, 149, 5423-5431.	2.8	130
42	Endogenous Allosteric Modulators of G Proteinâ€“Coupled Receptors. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 246-260.	2.5	127
43	The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. Cell, 2016, 165, 1632-1643.	28.9	126
44	A kinetic view of GPCR allostery and biased agonism. Nature Chemical Biology, 2017, 13, 929-937.	8.0	126
45	Allosteric Modulators of the Adenosine A₁ Receptor: Synthesis and Pharmacological Evaluation of 4-Substituted 2-Amino-3-benzoylthiophenes. Journal of Medicinal Chemistry, 2009, 52, 4543-4547.	6.4	124
46	Activation of the GLP-1 receptor by a non-peptidic agonist. Nature, 2020, 577, 432-436.	27.8	119
47	Biased Agonism and Biased Allosteric Modulation at the CB₁ Cannabinoid Receptor. Molecular Pharmacology, 2015, 88, 368-379.	2.3	118
48	Structural basis of G _s and G _i recognition by the human glucagon receptor. Science, 2020, 367, 1346-1352.	12.6	117
49	Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects. Molecular Pharmacology, 2012, 81, 41-52.	2.3	115
50	Allosteric Modulation of Muscarinic Acetylcholine Receptors. Current Neuropharmacology, 2007, 5, 157-167.	2.9	114
51	Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy. Cell, 2016, 167, 739-749.e11.	28.9	113
52	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Molecular Cell, 2020, 80, 485-500.e7.	9.7	111
53	Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-?, IL-1, and RANKL. Journal of Cellular Physiology, 2002, 190, 101-108.	4.1	110
54	Automatic local resolution-based sharpening of cryo-EM maps. Bioinformatics, 2020, 36, 765-772.	4.1	110

#	Article	IF	Citations
55	Localization of binding sites for calcitonin gene-related peptide in rat brain by in vitro autoradiography. Neuroscience, 1986, 19, 1235-1245.	2.3	108
56	A new mechanism of allostery in a G proteinâ€“coupled receptor dimer. Nature Chemical Biology, 2014, 10, 745-752.	8.0	108
57	Structure-Function Studies of Allosteric Agonism at M2Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2007, 72, 463-476.	2.3	105
58	New Insights into the Function of M₄ Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.3	104
59	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications, 2017, 8, 14232.	12.8	104
60	Evidence for a new subclass of calcitonin/ calcitonin gene-related peptide binding site in rat brain. Neurochemistry International, 1988, 12, 323-335.	3.8	98
61	A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation. Journal of Biological Chemistry, 2012, 287, 650-659.	3.4	98
62	Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11927-11932.	7.1	97
63	Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. ACS Pharmacology and Translational Science, 2018, 1, 12-20.	4.9	96
64	Biased Agonism of Endogenous Opioid Peptides at theÎ¼-Opioid Receptor. Molecular Pharmacology, 2015, 88, 335-346.	2.3	93
65	Rules of Engagement: GPCRs and G Proteins. ACS Pharmacology and Translational Science, 2018, 1, 73-83.	4.9	93
66	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4614-4619.	7.1	92
67	Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. Molecular Cell, 2020, 77, 656-668.e5.	9.7	92
68	Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. Chemical Reviews, 2017, 117, 111-138.	47.7	91
69	Determinants of 1-Piperidinecarboxamide, N-[2-[[5-Amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dih (BIBN4096BS) Affinity for Calcitonin Gene-Related Peptide and Amylin Receptorsâ€"The Role of Receptor Activity Modifying Protein 1. Molecular Pharmacology, 2006, 70, 1984-1991.	2.3	88
70	G Proteinâ€“Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. Pharmacological Reviews, 2018, 70, 39-67.	16.0	88
71	Calcitonin receptor antibodies in the identification of osteoclasts. Bone, 1999, 25, 1-8.	2.9	87
72	â€˜Ins and outsâ€™ of seven-transmembrane receptor signalling to ERK. Trends in Endocrinology and Metabolism, 2005, 16, 26-33.	7.1	86

#	Article	IF	Citations
73	Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. Journal of Neurochemistry, 2005, 93, 1603-1615.	3.9	85
74	Procalcitonin has bioactivity at calcitonin receptor family complexes: Potential mediator implications in sepsis*. Critical Care Medicine, 2008, 36, 1637-1640.	0.9	85
75	Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Research, 2016, 26, 574-592.	12.0	85
76	Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Molecular Neurobiology, 1991, 5, 251-273.	4.0	84
77	Allosteric Modulation of G Protein-Coupled Receptors. Current Pharmaceutical Design, 2004, 10, 2003-2013.	1.9	84
78	Polymorphism and Ligand Dependent Changes in Human Glucagon-Like Peptide-1 Receptor (GLP-1R) Function: Allosteric Rescue of Loss of Function Mutation. Molecular Pharmacology, 2011, 80, 486-497.	2.3	84
79	A Nuclear Transport Inhibitor That Modulates the Unfolded Protein Response and Provides In Vivo Protection Against Lethal Dengue virus Infection. Journal of Infectious Diseases, 2014, 210, 1780-1791.	4.0	84
80	Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia. Nature, 2021, 597, 571-576.	27.8	84
81	RAMPs: 5 years on, where to now?. Trends in Pharmacological Sciences, 2003, 24, 596-601.	8.7	83
82	Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Has a Critical Role in GLP-1 Peptide Binding and Receptor Activation. Journal of Biological Chemistry, 2012, 287, 3642-3658.	3.4	83
83	Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5675-84.	7.1	82
84	The Relaxin Family Peptide Receptor 3 Activates Extracellular Signal-Regulated Kinase 1/2 through a Protein Kinase C-Dependent Mechanism. Molecular Pharmacology, 2007, 71, 1618-1629.	2.3	81
85	Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 125-135.	3.4	81
86	Amylin receptors: molecular composition and pharmacology. Biochemical Society Transactions, 2004, 32, 865-867.	3.4	78
87	Comparative distribution off receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Canadian Journal of Physiology and Pharmacology, 1995, 73, 1037-1041.	1.4	77
88	Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecule Ligands. Molecular Pharmacology, 2013, 83, 822-834.	2.3	77
89	Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function. Molecular and Cellular Endocrinology, 2000, 162, 35-43.	3.2	74
90	Molecular Pharmacology of the Calcitonin Receptor. Receptors and Channels, 2002, 8, 243-255.	1.1	73

#	Article	IF	Citations
91	Complexing Receptor Pharmacology: Modulation of Family B G Protein-Coupled Receptor Function by RAMPs. Annals of the New York Academy of Sciences, 2006, 1070, 90-104.	3.8	72
92	Identification of Molecular Phenotypes and Biased Signaling Induced by Naturally Occurring Mutations of the Human Calcium-Sensing Receptor. Endocrinology, 2012, 153, 4304-4316.	2.8	72
93	Multiple Ramp Domains Are Required for Generation of Amylin Receptor Phenotype from the Calcitonin Receptor Gene Product. Biochemical and Biophysical Research Communications, 2000, 267, 368-372.	2.1	71
94	Biased allosteric modulation at the <scp>CaS</scp> receptor engendered by structurally diverse calcimimetics. British Journal of Pharmacology, 2015, 172, 185-200.	5.4	71
95	Structure and Dynamics of Adrenomedullin Receptors AM₁ and AM₂ Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. ACS Pharmacology and Translational Science, 2020, 3, 263-284.	4.9	71
96	The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Seminars in Cell and Developmental Biology, 2004, 15, 299-308.	5.0	70
97	Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2010, 285, 19012-19021.	3.4	70
98	Molecular Basis for Hormone Recognition and Activation of Corticotropin-Releasing Factor Receptors. Molecular Cell, 2020, 77, 669-680.e4.	9.7	70
99	Identification of N-Terminal Receptor Activity-Modifying Protein Residues Important for Calcitonin Gene-Related Peptide, Adrenomedullin, and Amylin Receptor Function. Molecular Pharmacology, 2008, 74, 1059-1071.	2.3	69
100	Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery. Molecular Pharmacology, 2012, 82, 281-290.	2.3	69
101	Î²-Arrestin-Biased Agonists of the GLP-1 Receptor from Î²-Amino Acid Residue Incorporation into GLP-1 Analogues. Journal of the American Chemical Society, 2016, 138, 14970-14979.	13.7	69
102	Impact of Clinically Relevant Mutations on the Pharmacoregulation and Signaling Bias of the Calcium-Sensing Receptor by Positive and Negative Allosteric Modulators. Endocrinology, 2013, 154, 1105-1116.	2.8	68
103	Biologically active salmon calcitonin-like peptide is present in rat brain. Brain Research, 1992, 596, 279-284.	2.2	67
104	Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 540-550.	2.5	67
105	Allostery in GPCRs: â€˜MWCâ€™ revisited. Trends in Biochemical Sciences, 2011, 36, 663-672.	7.5	64
106	Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia, 2004, 18, 1505-1511.	7.2	62
107	Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18607-18612.	7.1	62
108	Constitutive Formation of Oligomeric Complexes between Family B G Protein-Coupled Vasoactive Intestinal Polypeptide and Secretin Receptors. Molecular Pharmacology, 2006, 69, 363-373.	2.3	61

#	Article	IF	Citations
109	Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M₁Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2010, 78, 94-104.	2.3	61
110	Impact of species variability and â€˜probeâ€dependenceâ€™ on the detection andin vivovalidation of allosteric modulation at the M₄muscarinic acetylcholine receptor. British Journal of Pharmacology, 2011, 162, 1659-1670.	5.4	60
111	Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias. PLoS ONE, 2014, 9, e92042.	2.5	60
112	In vitro autoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain. Neuroscience, 1995, 69, 1223-1237.	2.3	59
113	In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain. Journal of Chemical Neuroanatomy, 2004, 27, 217-236.	2.1	59
114	Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochemical Society Transactions, 2013, 41, 172-179.	3.4	59
115	Quantification of adenosine A 1 receptor biased agonism: Implications for drug discovery. Biochemical Pharmacology, 2016, 99, 101-112.	4.4	58
116	Structure-based discovery of selective positive allosteric modulators of antagonists for the M ₂ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2419-E2428.	7.1	57
117	Structure and dynamics of the CGRP receptor in apo and peptide-bound forms. Science, 2021, 372, .	12.6	57
118	Distinct Receptor Activity-Modifying Protein Domains Differentially Modulate Interaction with Calcitonin Receptors. Molecular Pharmacology, 2006, 69, 1984-1989.	2.3	56
119	Role of the Second Extracellular Loop of the Adenosine A₁ Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. Molecular Pharmacology, 2016, 90, 715-725.	2.3	56
120	A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures. Molecular Pharmacology, 2016, 89, 335-347.	2.3	56
121	M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. Journal of Clinical Investigation, 2016, 127, 487-499.	8.2	56
122	Modulating receptor function through RAMPs: can they represent drug targets in themselves?. Drug Discovery Today, 2009, 14, 413-419.	6.4	55
123	Molecular Mechanisms of Bitopic Ligand Engagement with the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 23817-23837.	3.4	55
124	2-Aminothienopyridazines as Novel Adenosine A1 Receptor Allosteric Modulators and Antagonists. Journal of Medicinal Chemistry, 2008, 51, 6165-6172.	6.4	54
125	G-protein-coupled receptor allosterism: the promise and the problem(s). Biochemical Society Transactions, 2004, 32, 873-877.	3.4	53
126	Synthesis and Characterization of Novel 2-Amino-3-benzoylthiophene Derivatives as Biased Allosteric Agonists and Modulators of the Adenosine A₁ Receptor. Journal of Medicinal Chemistry, 2012, 55, 2367-2375.	6.4	53

#	Article	IF	Citations
127	Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M₁ Muscarinic Receptor. Journal of Medicinal Chemistry, 2013, 56, 5151-5172.	6.4	53
128	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. Molecular Pharmacology, 2016, 90, 703-714.	2.3	53
129	Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1. Biochemical Pharmacology, 2017, 136, 99-108.	4.4	53
130	Localization and characterization of renal calcitonin receptors by in vitro autoradiography. Kidney International, 1987, 32, 862-868.	5.2	52
131	Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1062-1072.	2.5	52
132	Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin. Molecular Pharmacology, 2012, 82, 1066-1073.	2.3	51
133	Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 6067-6079.	3.4	51
134	Recent advances in the determination of G protein-coupled receptor structures. Current Opinion in Structural Biology, 2018, 51, 28-34.	5.7	51
135	Mini ReviewCalcitonin. Growth Factors, 2004, 22, 217-224.	1.7	50
136	The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. Brain Research, 2010, 1343, 153-167.	2.2	50
137	Functional Importance of a Structurally Distinct Homodimeric Complex of the Family B G Protein-Coupled Secretin Receptor. Molecular Pharmacology, 2009, 76, 264-274.	2.3	49
138	Refinement of Glucagon-like Peptide 1 Docking to Its Intact Receptor Using Mid-region Photolabile Probes and Molecular Modeling. Journal of Biological Chemistry, 2011, 286, 15895-15907.	3.4	49
139	Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor. Journal of Biological Chemistry, 2014, 289, 33701-33711.	3.4	49
140	Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. Biochemical Pharmacology, 2016, 113, 70-87.	4.4	48
141	Crystal structure of the M ₅ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26001-26007.	7.1	48
142	Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nature Communications, 2019, 10, 3289.	12.8	47
143	Determination of Adenosine A₁Receptor Agonist and Antagonist Pharmacology UsingSaccharomyces cerevisiae: Implications for Ligand Screening and Functional Selectivity. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 277-286.	2.5	46
144	Structure and dynamics of the active Gs-coupled human secretin receptor. Nature Communications, 2020, 11, 4137.	12.8	46

#	Article	IF	Citations
145	Molecular Basis of Association of Receptor Activity-Modifying Protein 3 with the Family B G Protein-Coupled Secretin Receptor. Biochemistry, 2009, 48, 11773-11785.	2.5	45
146	Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists. Biochemical Pharmacology, 2018, 156, 406-419.	4.4	45
147	Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor. Journal of Molecular Neuroscience, 2008, 36, 279-285.	2.3	44
148	Consequences of splice variation on Secretin family G proteinâ€coupled receptor function. British Journal of Pharmacology, 2012, 166, 98-109.	5.4	44
149	An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discovery, 2016, 2, 16012.	6.7	44
150	From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. Cell, 2021, 184, 5886-5901.e22.	28.9	44
151	Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. Journal of Biological Chemistry, 2018, 293, 9370-9387.	3.4	43
152	Structure/Function Relationships of Calcitonin Analogues as Agonists, Antagonists, or Inverse Agonists in a Constitutively Activated Receptor Cell System. Molecular Pharmacology, 1997, 51, 658-665.	2.3	42
153	Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants. PLoS ONE, 2016, 11, e0146846.	2.5	42
154	A Critical Role for the Short Intracellular C Terminus in Receptor Activity-Modifying Protein Function. Molecular Pharmacology, 2006, 70, 1750-1760.	2.3	41
155	3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorganic and Medicinal Chemistry, 2009, 17, 7353-7361.	3.0	41
156	Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. Trends in Pharmacological Sciences, 2015, 36, 215-225.	8.7	41
157	Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. Biochemical Pharmacology, 2016, 118, 68-87.	4.4	41
158	Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R). Journal of Biological Chemistry, 2017, 292, 7131-7144.	3.4	41
159	Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biology, 2021, 19, e3001295.	5.6	41
160	Characterization of Amylin and Calcitonin Receptor Binding in the Mouse Î±-Thyroid-Stimulating Hormone Thyrotroph Cell Line*. Endocrinology, 1997, 138, 3486-3496.	2.8	39
161	Delineating the Mode of Action of Adenosine A₁ Receptor Allosteric Modulators. Molecular Pharmacology, 2010, 78, 444-455.	2.3	39
162	Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors. Journal of General Physiology, 2018, 150, 1360-1372.	1.9	38

#	Article	IF	Citations
163	The Molecular Control of Calcitonin Receptor Signaling. ACS Pharmacology and Translational Science, 2019, 2, 31-51.	4.9	38
164	Angiotensin II Receptors in the Kidney. American Journal of Hypertension, 1990, 3, 250-255.	2.0	37
165	Engendering biased signalling from the calciumâ€sensing receptor for the pharmacotherapy of diverse disorders. British Journal of Pharmacology, 2014, 171, 1142-1155.	5.4	37
166	Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochemical Pharmacology, 2020, 177, 114001.	4.4	37
167	Routine sub-2.5â€‰Ã… cryo-EM structure determination of GPCRs. Nature Communications, 2021, 12, 4333.	12.8	37
168	Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. Endocrinology, 1994, 135, 183-190.	2.8	37
169	Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors. Current Pharmaceutical Design, 2006, 12, 1683-1702.	1.9	36
170	Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nature Chemical Biology, 2020, 16, 240-249.	8.0	36
171	Spatial Proximity between a Photolabile Residue in Position 19 of Salmon Calcitonin and the Amino Terminus of the Human Calcitonin Receptor. Journal of Biological Chemistry, 2004, 279, 6720-6729.	3.4	35
172	Molecular Approximations between Residues 21 and 23 of Secretin and Its Receptor: Development of a Model for Peptide Docking with the Amino Terminus of the Secretin Receptor. Molecular Pharmacology, 2007, 72, 280-290.	2.3	35
173	Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB Journal, 2012, 26, 5092-5105.	0.5	35
174	4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M₁ Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2016, 59, 388-409.	6.4	35
175	O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity. Journal of the American Chemical Society, 2019, 141, 14210-14219.	13.7	35
176	Spatial Approximation between Secretin Residue Five and the Third Extracellular Loop of Its Receptor Provides New Insight into the Molecular Basis of Natural Agonist Binding. Molecular Pharmacology, 2008, 74, 413-422.	2.3	34
177	Overview of Receptor Allosterism. Current Protocols in Pharmacology, 2010, 51, Unit 1.21.	4.0	34
178	GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1â€“2 September 2014. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 883-903.	3.0	34
179	Purification of Calcitonin-Like Peptides from Rat Brain and Pituitary*. Endocrinology, 1998, 139, 982-992.	2.8	33
180	H2 Relaxin Is a Biased Ligand Relative to H3 Relaxin at the Relaxin Family Peptide Receptor 3 (RXFP3). Molecular Pharmacology, 2010, 77, 759-772.	2.3	33

#	Article	IF	Citations
181	Muscarinic M5 receptors modulate ethanol seeking in rats. Neuropsychopharmacology, 2018, 43, 1510-1517.	5.4	33
182	Responses of GPCR135 to Human Gene 3 (H3) Relaxin in CHO-K1 Cells Determined by Microphysiometry. Annals of the New York Academy of Sciences, 2005, 1041, 332-337.	3.8	32
183	The Role of Transmembrane Domain 3 in the Actions of Orthosteric, Allosteric, and Atypical Agonists of the M₄Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2011, 79, 855-865.	2.3	32
184	G-Protein-coupled receptor-protein interactions: Basis for new concepts on receptor structure and function. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 979-987.	1.9	31
185	Regulation of M₂Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 382-390.	2.5	31
186	Effects of Conformational Restriction of 2-Amino-3-benzoylthiophenes on A₁ Adenosine Receptor Modulation. Journal of Medicinal Chemistry, 2010, 53, 6550-6559.	6.4	31
187	Molecular Basis of Secretin Docking to Its Intact Receptor Using Multiple Photolabile Probes Distributed throughout the Pharmacophore. Journal of Biological Chemistry, 2011, 286, 23888-23899.	3.4	31
188	Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor. Molecular Pharmacology, 2013, 84, 425-437.	2.3	31
189	Allosteric Modulation of M1 Muscarinic Acetylcholine Receptor Internalization and Subcellular Trafficking. Journal of Biological Chemistry, 2014, 289, 15856-15866.	3.4	31
190	Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide. Journal of Biological Chemistry, 2020, 295, 9313-9325.	3.4	31
191	Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Differentially Regulates Orthosteric but Not Allosteric Agonist Binding and Function. Journal of Biological Chemistry, 2012, 287, 3659-3673.	3.4	30
192	Minireview: Signal Bias, Allosterism, and Polymorphic Variation at the GLP-1R: Implications for Drug Discovery. Molecular Endocrinology, 2013, 27, 1234-1244.	3.7	30
193	Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. Frontiers in Pharmacology, 2020, 11, 606656.	3.5	30
194	Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation. Nature Communications, 2022, 13, 92.	12.8	30
195	Divergent effects of strontium and calciumâ€sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. British Journal of Pharmacology, 2018, 175, 4095-4108.	5.4	29
196	Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research. PLoS ONE, 2018, 13, e0197177.	2.5	29
197	Evolving cryo-EM structural approaches for GPCR drug discovery. Structure, 2021, 29, 963-974.e6.	3.3	29
198	Stimulus Bias Provides Evidence for Conformational Constraints in the Structure of a G Protein-coupled Receptor. Journal of Biological Chemistry, 2012, 287, 37066-37077.	3.4	28

#	Article	IF	Citations
199	The complexity of signalling mediated by the glucagon-like peptide-1 receptor. Biochemical Society Transactions, 2016, 44, 582-588.	3.4	28
200	Light-activated chimeric GPCRs: limitations and opportunities. Current Opinion in Structural Biology, 2019, 57, 196-203.	5.7	28
201	Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors. ACS Pharmacology and Translational Science, 2020, 3, 246-262.	4.9	28
202	A structural basis for amylin receptor phenotype. Science, 2022, 375, eabm9609.	12.6	28
203	Photoaffinity scanning in the mapping of the peptide receptor interface of class II G proteinâ€"coupled receptors. Journal of Peptide Science, 2004, 10, 179-203.	1.4	27
204	Insights into Interactions between the Î±-Helical Region of the Salmon Calcitonin Antagonists and the Human Calcitonin Receptor using Photoaffinity Labeling. Journal of Biological Chemistry, 2005, 280, 28610-28622.	3.4	27
205	Fluorescence Resonance Energy Transfer Analysis of Secretin Docking to Its Receptor. Journal of Biological Chemistry, 2007, 282, 32834-32843.	3.4	27
206	Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4401-4404.	2.2	27
207	Synthesis and Pharmacological Evaluation of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) Designed to Bind Irreversibly to an Allosteric Site of the M1Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry, 2014, 57, 5405-5418.	6.4	27
208	AM833 Is a Novel Agonist of Calcitonin Family G Proteinâ€"Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 417-440.	2.5	27
209	Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Reports, 2021, 36, 109374.	6.4	27
210	Interaction Studies of Multiple Binding Sites on M₄ Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2006, 70, 736-746.	2.3	26
211	The synthesis and biological evaluation of 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophenes as allosteric modulators of the A1 adenosine receptor. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3704-3707.	2.2	26
212	Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regulatory Peptides, 2010, 164, 113-119.	1.9	25
213	Structural and functional insights into the juxtamembranous aminoâ€terminal tail and extracellular loop regions of class <scp>B GPCRs</scp>. British Journal of Pharmacology, 2014, 171, 1085-1101.	5.4	25
214	Bitopic Binding Mode of an M₁ Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Molecular Pharmacology, 2018, 93, 645-656.	2.3	25
215	Involvement of the sigma₁ (Ïƒ₁) receptor in the antiâ€amnesic, but not antidepressantâ€like, effects of the aminotetrahydrofuran derivative ANAVEX1â€41. British Journal of Pharmacology, 2007, 152, 267-279.	5.4	24
216	Detection of Novel Functional Selectivity at M₃ Muscarinic Acetylcholine Receptors Using a Saccharomyces cerevisiae Platform. ACS Chemical Biology, 2010, 5, 365-375.	3.4	24

#	Article	IF	Citations
217	Allosteric Modulation of a Chemogenetically Modified G Protein-Coupled Receptor. Molecular Pharmacology, 2013, 83, 521-530.	2.3	24
218	Molecular Mechanisms of Action of M₅ Muscarinic Acetylcholine Receptor Allosteric Modulators. Molecular Pharmacology, 2016, 90, 427-436.	2.3	24
219	Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. Biochemical Pharmacology, 2018, 150, 214-244.	4.4	24
220	Structural and functional diversity among agonist-bound states of the GLP-1 receptor. Nature Chemical Biology, 2022, 18, 256-263.	8.0	24
221	Relaxin Receptors - New Drug Targets for Multiple Disease States. Current Drug Targets, 2007, 8, 91-104.	2.1	23
222	Molecular Basis for Binding and Subtype Selectivity of 1,4-Benzodiazepine Antagonist Ligands of the Cholecystokinin Receptor. Journal of Biological Chemistry, 2012, 287, 18618-18635.	3.4	23
223	Use of Backbone Modification To Enlarge the Spatiotemporal Diversity of Parathyroid Hormone Receptor-1 Signaling via Biased Agonism. Journal of the American Chemical Society, 2019, 141, 14486-14490.	13.7	23
224	Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochemical Pharmacology, 2020, 180, 114150.	4.4	23
225	Structureâ€“function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors. Peptides, 2011, 32, 1060-1067.	2.4	22
226	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology, 2019, 144, 244-255.	4.1	22
227	Electrophoretic Mobility and Glycosylation Characteristics of Heterogeneously Expressed Calcitonin Receptors¹. Endocrinology, 1997, 138, 530-539.	2.8	21
228	Secretin Occupies a Single Protomer of the Homodimeric Secretin Receptor Complex. Journal of Biological Chemistry, 2010, 285, 9919-9931.	3.4	21
229	Positive Allosteric Modulation of the Muscarinic M₁Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 354-365.	2.5	21
230	Isoform-Specific Biased Agonism of Histamine H₃Receptor Agonists. Molecular Pharmacology, 2017, 91, 87-99.	2.3	21
231	Probing Structural Requirements of Positive Allosteric Modulators of the M₄ Muscarinic Receptor. Journal of Medicinal Chemistry, 2013, 56, 8196-8200.	6.4	20
232	Novel Irreversible Agonists Acting at the A₁ Adenosine Receptor. Journal of Medicinal Chemistry, 2016, 59, 11182-11194.	6.4	20
233	To Bind or Not to Bind: Unravelling GPCR Polypharmacology. Cell, 2018, 172, 636-638.	28.9	20
234	Pharmacology of 5HT2C receptor-mediated ERK1/2 phosphorylation: Agonist-specific activation pathways and the impact of RNA editing. Biochemical Pharmacology, 2008, 76, 1276-1287.	4.4	19

#	Article	IF	Citations
235	Prediction of Functionally Selective Allosteric Interactions at an M₃Muscarinic Acetylcholine Receptor Mutant Using Saccharomyces cerevisiae. Molecular Pharmacology, 2010, 78, 205-214.	2.3	19
236	Molecular Basis for Benzodiazepine Agonist Action at the Type 1 Cholecystokinin Receptor. Journal of Biological Chemistry, 2013, 288, 21082-21095.	3.4	19
237	Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms. Biochemical Pharmacology, 2018, 148, 111-129.	4.4	19
238	Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. Biochemical Pharmacology, 2018, 154, 243-254.	4.4	19
239	Differential Impact of Amino Acid Substitutions on Critical Residues of the Human Glucagon-Like Peptide-1 Receptor Involved in Peptide Activity and Small-Molecule Allostery. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 52-63.	2.5	18
240	Regulation of serotonin 5-HT2C receptors by chronic ligand exposure. European Journal of Pharmacology, 2004, 498, 59-69.	3.5	17
241	Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists. Molecular Pharmacology, 2015, 88, 779-790.	2.3	17
242	Characterization of Amylin and Calcitonin Receptor Binding in the Mouse Â-Thyroid-Stimulating Hormone Thyrotroph Cell Line. Endocrinology, 1997, 138, 3486-3496.	2.8	17
243	Membranes under the Magnetic Lens: A Dive into the Diverse World of Membrane Protein Structures Using Cryo-EM. Chemical Reviews, 2022, 122, 13989-14017.	47.7	17
244	Structureâ€"Function Studies of Muscarinic Acetylcholine Receptors. Handbook of Experimental Pharmacology, 2012, , 29-48.	1.8	16
245	A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. BioTechniques, 2013, 54, 217-221.	1.8	16
246	Synthesis and Pharmacological Evaluation of M₄ Muscarinic Receptor Positive Allosteric Modulators Derived from VU10004. ACS Chemical Neuroscience, 2015, 6, 838-844.	3.5	16
247	In vitro autoradiographic localization of calcitonin binding sites in human medulla oblongata. Journal of Comparative Neurology, 1994, 341, 449-463.	1.6	15
248	Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. Journal of Medicinal Chemistry, 2015, 58, 9562-9577.	6.4	15
249	Vascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX. European Journal of Pharmacology, 2018, 829, 85-92.	3.5	15
250	Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas. BMC Cancer, 2019, 19, 157.	2.6	15
251	The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors. Regulatory Peptides, 2008, 145, 65-71.	1.9	14
252	Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor. Biochemical and Biophysical Research Communications, 2021, 578, 84-90.	2.1	14

#	Article	IF	Citations
253	Heterogeneity of the Calcitonin Receptor: Functional Aspects in Osteoclasts and Other Sites. Journal of Nutrition, 1995, 125, 2009S-2014S.	2.9	13
254	Quantification of Allosteric Interactions at G Proteinâ€“Coupled Receptors Using Radioligand Binding Assays. Current Protocols in Pharmacology, 2011, 52, Unit 1.22.	4.0	13
255	Discovery and Optimization of Potent and CNS Penetrant M₅-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. ACS Chemical Neuroscience, 2018, 9, 1572-1581.	3.5	13
256	Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney. American Journal of Physiology - Renal Physiology, 1998, 274, F51-F62.	2.7	12
257	Peptide-Oligonucleotide Hybrids in Antisense Therapy. Mini-Reviews in Medicinal Chemistry, 2005, 5, 41-55.	2.4	12
258	Monotreme glucagon-like peptide-1 in venom and gut: one gene â€“ two very different functions. Scientific Reports, 2016, 6, 37744.	3.3	12
259	Effects of urea pretreatment on the binding properties of adenosine A1 receptors. British Journal of Pharmacology, 2005, 146, 1119-1129.	5.4	11
260	The Impact of Orthosteric Radioligand Depletion on the Quantification of Allosteric Modulator Interactions. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 927-934.	2.5	11
261	Receptor Activity Modifying Proteins and Their Potential as Drug Targets. Progress in Molecular Biology and Translational Science, 2010, 91, 53-79.	1.7	11
262	Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening. PLoS ONE, 2017, 12, e0174719.	2.5	11
263	RAMPs as Drug Targets. Advances in Experimental Medicine and Biology, 2012, 744, 61-74.	1.6	10
264	Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding. Molecular Pharmacology, 2015, 87, 130-140.	2.3	10
265	Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M₁ Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2018, 94, 770-783.	2.3	10
266	Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics. Frontiers in Endocrinology, 2021, 12, 684656.	3.5	10
267	Amylin is an agonist of the renal porcine calcitonin receptor. Endocrinology, 1994, 134, 2103-2107.	2.8	10
268	Purification of Calcitonin-Like Peptides from Rat Brain and Pituitary. Endocrinology, 1998, 139, 982-992.	2.8	10
269	Development of a Photoactivatable Allosteric Ligand for the M₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2014, 5, 902-907.	3.5	9
270	Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor. Journal of Biological Chemistry, 2016, 291, 5172-5184.	3.4	9

#	Article	IF	Citations
271	Homology Modeling of GPCRs. Methods in Molecular Biology, 2009, 552, 97-113.	0.9	9
272	Localization and Regulation of Renal Receptors for Angiotensin II and Atrial Natriuretic Peptide.. Tohoku Journal of Experimental Medicine, 1992, 166, 41-56.	1.2	8
273	Calcium inflow in cells transfected with cloned rat and porcine calcitonin receptors. Biochimica Et Biophysica Acta - Molecular Cell Research, 1995, 1265, 213-219.	4.1	8
274	Detection and Quantification of Allosteric Modulation of Endogenous M4 Muscarinic Acetylcholine Receptor Using Impedance-Based Label-Free Technology in a Neuronal Cell Line. Journal of Biomolecular Screening, 2015, 20, 646-654.	2.6	8
275	Coding GPCR-G protein specificity. Cell Research, 2017, 27, 1193-1194.	12.0	8
276	Improving virtual screening of G protein-coupled receptors via ligand-directed modeling. PLoS Computational Biology, 2017, 13, e1005819.	3.2	8
277	Deconvoluting the Molecular Control of Binding and Signaling at the Amylin 3 Receptor: RAMP3 Alters Signal Propagation through Extracellular Loops of the Calcitonin Receptor. ACS Pharmacology and Translational Science, 2019, 2, 183-197.	4.9	8
278	A structureâ€“activity relationship study of the positive allosteric modulator LY2033298 at the M₄ muscarinic acetylcholine receptor. MedChemComm, 2015, 6, 1998-2003.	3.4	7
279	Prediction of Loops in G Protein-Coupled Receptor Homology Models: Effect of Imprecise Surroundings and Constraints. Journal of Chemical Information and Modeling, 2016, 56, 671-686.	5.4	7
280	High throughput, quantitative analysis of human osteoclast differentiation and activity. Analytical Biochemistry, 2017, 519, 51-56.	2.4	7
281	Structureâ€“Activity Relationships of Pan-GÎ±_{q/11} Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. ACS Chemical Neuroscience, 2018, 9, 1818-1828.	3.5	7
282	6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M₁ mAChR: The Determinants of Allosteric Activity. ACS Chemical Neuroscience, 2019, 10, 1099-1114.	3.5	7
283	Rational development of a high-affinity secretin receptor antagonist. Biochemical Pharmacology, 2020, 177, 113929.	4.4	7
284	The ontogeny of [125i]rat-Î±-cgrp binding sites in the spinal cord of sheep: A prenatal and postnatal study. Neuroscience, 1994, 62, 257-264.	2.3	6
285	Function of the Rat Calcitonin Receptors, C1a and C1b, Expressed inXenopusOocytes. Biochemical and Biophysical Research Communications, 1998, 242, 484-491.	2.1	6
286	Coexpressed Class B G Proteinâ€“Coupled Secretin and GLP-1 Receptors Self- and Cross-Associate: Impact on Pancreatic Islets. Endocrinology, 2017, 158, 1685-1700.	2.8	6
287	Correspondence: Reply to â€˜Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injuryâ€™. Nature Communications, 2018, 9, 530.	12.8	6
288	Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1. Biochemical Pharmacology, 2018, 156, 223-240.	4.4	6

#	Article	IF	Citations
289	Identification of a Novel Allosteric Site at the M5 Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2021, 12, 3112-3123.	3.5	6
290	Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms. BMJ Open Diabetes Research and Care, 2021, 9, e002285.	2.8	6
291	Meet the B family. Nature, 2013, 499, 417-418.	27.8	5
292	Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor. Molecular Pharmacology, 2019, 95, 245-259.	2.3	5
293	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Materials & Interfaces, 2020, 12, 20147-20148.	8.0	5
294	In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52. ACS Chemical Neuroscience, 2020, 11, 2066-2076.	3.5	5
295	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Frontiers in Pharmacology, 2021, 12, 628060.	3.5	5
296	Exploring Ligand Binding to Calcitonin Gene-Related Peptide Receptors. Frontiers in Molecular Biosciences, 2021, 8, 720561.	3.5	5
297	Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor. Biochemical Pharmacology, 2021, 192, 114715.	4.4	5
298	Implications of ligand-receptor binding kinetics on GLP-1R signalling. Biochemical Pharmacology, 2022, 199, 114985.	4.4	5
299	Development of Novel 4â€Arylpyridinâ€2â€one and 6â€Arylpyrimidinâ€4â€one Positive Allosteric Modulators of the M 1 Muscarinic Acetylcholine Receptor. ChemMedChem, 2021, 16, 216-233.	3.2	4
300	Neurotransmitters as Tools in the Mapping of the Human Brain. Advances in Behavioral Biology, 1995, , 1-24.	0.2	4
301	Electrophoretic Mobility and Glycosylation Characteristics of Heterogeneously Expressed Calcitonin Receptors. Endocrinology, 1997, 138, 530-539.	2.8	4
302	Cognitive behavioral markers of neurodevelopmental trajectories in rodents. Translational Psychiatry, 2021, 11, 556.	4.8	4
303	Calcitonin. , 2016, , 1004-1017.e5.		3
304	Utility of an â€œAllosteric Site-Impairedâ€•M₂Muscarinic Acetylcholine Receptor as a Novel Construct for Validating Mechanisms of Action of Synthetic and Putative Endogenous Allosteric Modulators. Molecular Pharmacology, 2018, 94, 1298-1309.	2.3	3
305	Targeting Antibiotic Resistance: From Diagnostics to Novel Antibiotics. ACS Pharmacology and Translational Science, 2020, 3, 371-372.	4.9	3
306	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of the American Chemical Society, 2020, 142, 8059-8060.	13.7	3

#	Article	IF	Citations
307	Understanding Amylin Receptors. , 2010, , 41-57.		3
308	Calcitonin. , 2003, , 220-230.		3
309	Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol. Frontiers in Endocrinology, 2021, 12, 789957.	3.5	3
310	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Nano, 2020, 14, 5151-5152.	14.6	2
311	Addition of a Carboxy-Terminal Green Fluorescent Protein Does Not Alter the Binding and Signaling Properties of Relaxin Family Peptide Receptor 3. Annals of the New York Academy of Sciences, 2009, 1160, 105-107.	3.8	1
312	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Energy Letters, 2020, 5, 1610-1611.	17.4	1
313	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Environmental Science and Technology Letters, 2020, 7, 280-281.	8.7	1
314	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Education, 2020, 97, 1217-1218.	2.3	1
315	Restoring Agonist Function at a Chemogenetically Modified M₁ Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2020, 11, 4270-4279.	3.5	1
316	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Crystal Growth and Design, 2020, 20, 2817-2818.	3.0	1
317	Thermo Scientificâ„¢ Glacios Cryo-TEM: A Versatile 200 kV Tool for Structure-Based Drug Discovery. Microscopy and Microanalysis, 2021, 27, 3256-3258.	0.4	1
318	Calcitonin. , 2010, , 1074-1088.		1
319	Homologous regulation of the rat C1a calcitonin receptor (CTR) in nonosteoclastic cells is independent of CTR messenger ribonucleic acid changes and cyclic adenosine 3',5'-monophosphate-dependent protein kinase activation. Endocrinology, 1996, 137, 4576-4585.	2.8	1
320	Calcitonin/Amylin Receptors and Ramps. Scientific World Journal, The, 2001, 1, 9-9.	2.1	0
321	Application of photoaffinity crosslinking in determining the interaction between calcitonin and its receptor. International Journal of Peptide Research and Therapeutics, 2003, 10, 447-453.	0.1	0
322	Application of photoaffinity crosslinking in determining the interaction between calcitonin and its receptor. International Journal of Peptide Research and Therapeutics, 2003, 10, 447-453.	1.9	0
323	Editorial [Hot Topic: G Protein-Coupled Receptor Drug Targets (Executive Editors: P.M. Sexton and A.) Tj ETQq1 1 0.784314 rgBT /Ove	1.9	0
324	Correction to â€œPolymorphism and Ligand Dependent Changes in Human Glucagon-Like Peptide-1 Receptor (GLP-1R) Function: Allosteric Rescue of Loss of Function Mutationâ€• Molecular Pharmacology, 2012, 82, 142-142.	2.3	0

#	Article	IF	Citations
325	Mapping Interactions Between the Amino-Terminal Region of Secretin and its Receptor using Disulfide-Trapping. Biophysical Journal, 2012, 102, 515a.	0.5	0
326	Correction to â€œDifferential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecular Ligandsâ€• Molecular Pharmacology, 2013, 84, 170-170.	2.3	0
327	CGRP/Adrenomedullin. , 2013, , 744-751.		0
328	Structural Basis for Modulation of a GPCR by Allosteric Drugs. Biophysical Journal, 2014, 106, 100a.	0.5	0
329	What determines the magnitude of cellular response for activation of G protein-coupled receptors?. Cell Cycle, 2017, 16, 392-394.	2.6	0
330	Ramp. , 2018, , 4433-4438.		0
331	Call for Papers: â€œAntibioticsâ€•â€" A Joint Special Issue of ACS Pharmacology & Translational Science and ACS Infectious Diseases. ACS Pharmacology and Translational Science, 2019, 2, 217-217.	4.9	0
332	ACS Pharmacology & Translational Science in 2019. ACS Pharmacology and Translational Science, 2019, 2, 1-1.	4.9	0
333	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Biomaterials Science and Engineering, 2020, 6, 2707-2708.	5.2	0
334	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Central Science, 2020, 6, 589-590.	11.3	0
335	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Chemical Biology, 2020, 15, 1282-1283.	3.4	0
336	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Chemical Neuroscience, 2020, 11, 1196-1197.	3.5	0
337	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Earth and Space Chemistry, 2020, 4, 672-673.	2.7	0
338	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Macro Letters, 2020, 9, 666-667.	4.8	0
339	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. , 2020, 2, 563-564.		0
340	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Photonics, 2020, 7, 1080-1081.	6.6	0
341	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Pharmacology and Translational Science, 2020, 3, 455-456.	4.9	0
342	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Sustainable Chemistry and Engineering, 2020, 8, 6574-6575.	6.7	0

#	Article	IF	Citations
343	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Analytical Chemistry, 2020, 92, 6187-6188.	6.5	0
344	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Chemistry of Materials, 2020, 32, 3678-3679.	6.7	0
345	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Proteome Research, 2020, 19, 1883-1884.	3.7	0
346	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Polymer Materials, 2020, 2, 1739-1740.	4.4	0
347	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Combinatorial Science, 2020, 22, 223-224.	3.8	0
348	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Medicinal Chemistry Letters, 2020, 11, 1060-1061.	2.8	0
349	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Biochemistry, 2020, 59, 1641-1642.	2.5	0
350	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical & Engineering Data, 2020, 65, 2253-2254.	1.9	0
351	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Organic Process Research and Development, 2020, 24, 872-873.	2.7	0
352	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Omega, 2020, 5, 9624-9625.	3.5	0
353	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Electronic Materials, 2020, 2, 1184-1185.	4.3	0
354	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry C, 2020, 124, 9629-9630.	3.1	0
355	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry Letters, 2020, 11, 3571-3572.	4.6	0
356	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Synthetic Biology, 2020, 9, 979-980.	3.8	0
357	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Energy Materials, 2020, 3, 4091-4092.	5.1	0
358	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Theory and Computation, 2020, 16, 2881-2882.	5.3	0
359	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Agricultural and Food Chemistry, 2020, 68, 5019-5020.	5.2	0
360	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry B, 2020, 124, 3603-3604.	2.6	0

#	Article	IF	Citations
361	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Nano Materials, 2020, 3, 3960-3961.	5.0	0
362	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Natural Products, 2020, 83, 1357-1358.	3.0	0
363	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Bioconjugate Chemistry, 2020, 31, 1211-1212.	3.6	0
364	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Health and Safety, 2020, 27, 133-134.	2.1	0
365	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Chemical Research in Toxicology, 2020, 33, 1509-1510.	3.3	0
366	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Energy & Fuels, 2020, 34, 5107-5108.	5.1	0
367	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Applied Bio Materials, 2020, 3, 2873-2874.	4.6	0
368	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Organic Chemistry, 2020, 85, 5751-5752.	3.2	0
369	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of the American Society for Mass Spectrometry, 2020, 31, 1006-1007.	2.8	0
370	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Accounts of Chemical Research, 2020, 53, 1001-1002.	15.6	0
371	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Biomacromolecules, 2020, 21, 1966-1967.	5.4	0
372	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Chemical Reviews, 2020, 120, 3939-3940.	47.7	0
373	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Environmental Science & Technology, 2020, 54, 5307-5308.	10.0	0
374	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Langmuir, 2020, 36, 4565-4566.	3.5	0
375	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Molecular Pharmaceutics, 2020, 17, 1445-1446.	4.6	0
376	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Infectious Diseases, 2020, 6, 891-892.	3.8	0
377	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Medicinal Chemistry, 2020, 63, 4409-4410.	6.4	0
378	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Physical Chemistry A, 2020, 124, 3501-3502.	2.5	0

#	Article	IF	Citations
379	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Nano Letters, 2020, 20, 2935-2936.	9.1	0
380	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. ACS Sensors, 2020, 5, 1251-1252.	7.8	0
381	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Journal of Chemical Information and Modeling, 2020, 60, 2651-2652.	5.4	0
382	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Industrial & Engineering Chemistry Research, 2020, 59, 8509-8510.	3.7	0
383	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Inorganic Chemistry, 2020, 59, 5796-5797.	4.0	0
384	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Organometallics, 2020, 39, 1665-1666.	2.3	0
385	Update to Our Reader, Reviewer, and Author Communitiesâ€"April 2020. Organic Letters, 2020, 22, 3307-3308.	4.6	0
386	CGRP and Adrenomedullin in the Brain. , 2006, , 771-778.		0
387	Ramp3. The AFCS-nature Molecule Pages, 0, , .	0.2	0
388	Ramp2. The AFCS-nature Molecule Pages, 0, , .	0.2	0
389	Characterisation of the adenosine A1 receptor in Saccharomyces cerevisiae. FASEB Journal, 2008, 22, 727.2.	0.5	0
390	Binding and functional characterisation of allosteric agonists at M2 muscarinic acetylcholine receptors. FASEB Journal, 2008, 22, 724.6.	0.5	0
391	Relaxin family peptide receptor 3. The AFCS-nature Molecule Pages, 0, , .	0.2	0
392	Ramp. , 2016, , 1-5.		0
393	Secretin amino-terminal structure-activity relationships and complementary mutagenesis at the site of docking to the secretin receptor. Molecular Pharmacology, 2022, , MOLPHARM-AR-2022-000502.	2.3	0
394	Second Messenger Assays for G Protein-Coupled Receptors: cAMP, Ca2+, Inositol Phosphates, ERK1/2. , 0, , 31-52.		0